EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study

Palak J Trivedi iD, Katherine Arndtz, Nadir Abbas, Alison Telford, Liam Young, Rajarshi Banerjee, Peter Eddowes, Kartik S Jhaveri, Gideon M Hirschfield iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Palak J Trivedi und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research and Gast…. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Cholangiopancreatography, Magnetic Resonance. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, National Institute for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Imaging markers of biliary disease in primary sclerosing cholangitis (PSC) have potential for use in clinical and trial disease monitoring. Herein, we evaluate how quantitative magnetic resonance cholangiopancreatography (MRCP) metrics change over time, as per the natural history of disease.

Methods

Individuals with PSC were prospectively scanned using non‐contrast MRCP. Quantitative metrics were calculated using MRCP+ post‐processing software to assess duct diameters and dilated and strictured regions. Additionally, a hepatopancreatobiliary radiologist (blinded to clinical details, biochemistry and quantitative biliary metrics) reported each scan, including ductal disease assessment according to the modified Amsterdam Cholangiographic Score (MAS).

Results

At baseline, 14 quantitative MRCP+ metrics were found to be significantly different in patients with PSC ( N = 55) compared to those with primary biliary cholangitis ( N = 55), autoimmune hepatitis ( N = 57) and healthy controls ( N = 18). In PSC specifically, baseline metrics quantifying the number of strictures and the number and length of bile ducts correlated with the MAS, transient elastography and serum ALP values ( p < 0.01 for all correlations). Over a median 371‐day follow‐up (range: 364–462), 29 patients with PSC underwent repeat MRCP, of whom 15 exhibited quantitative changes in MRCP+ metrics. Compared to baseline, quantitative MRCP+ identified an increasing number of strictures over time ( p < 0.05). Comparatively, no significant differences in biochemistry, elastography or the MAS were observed between timepoints. Quantitative MRCP+ metrics remained stable in non‐PSC liver disease.

Conclusion

Quantitative MRCP+ identifies changes in ductal disease over time in PSC, despite stability in biochemistry, liver stiffness and radiologist‐derived cholangiographic assessment (trial registration: ISRCTN39463479).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingCholangiopancreatography, Magnetic ResonanceHumansProspective StudiesFemaleMaleMiddle AgedAdultAgedBile DuctsYoung Adult

Autor:innen und Institutionen

  • National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research and Gastrointestinal Research, National Institute of Health Research (NIHR) Bi…
  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Liver Unit, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK.
  • Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Perspectum Ltd, Oxford, UK.
  • NIHR Nottingham BRC, University of Nottingham, Nottingham, UK.

ORCID-Profile: Palak J Trivedi, Gideon M Hirschfield

Förderung

  • National Institute for Health and Care Research
  • National Institute for Health Research

Zitieren

APA

Trivedi, P. J., Arndtz, K., Abbas, N., Telford, A., Young, L., Banerjee, R., Eddowes, P., Jhaveri, K. S., & Hirschfield, G. M. (2024). Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17944

Vancouver

Trivedi PJ, Arndtz K, Abbas N, Telford A, Young L, Banerjee R, et al. Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17944

BibTeX
@article{Trivedi2024,
  author = {Trivedi, Palak J and Arndtz, Katherine and Abbas, Nadir and Telford, Alison and Young, Liam and Banerjee, Rajarshi and Eddowes, Peter and Jhaveri, Kartik S and Hirschfield, Gideon M},
  title = {Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17944}
}
Kostenlos starten →